<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Fresenius Medical Care AG（FMS,FME.DE）的股票在德国交易中下跌约 4%，在纽约证券交易所的盘前交易中也出现类似情况，此前该公司报告第一季度利润和收入下降。此外，这家德国肾病患者产品和服务的供应商维持了 2026 财年的展望。</p>
<p>在第一季度，归属于股东的净收入从去年的 1.51 亿欧元下降 22%，降至 1.18 亿欧元。基本每股收益从去年的 0.52 欧元下降 17%，降至 0.43 欧元。</p>
<p>调整后的净收入为 2.51 亿欧元，或每股 0.91 欧元，而去年同期为 2.46 亿欧元，或每股 0.84 欧元。</p>
<p>在第一季度，集团营业收入从去年下降 14%，降至 2.86 亿欧元，利润率从去年的 6.8% 降至 6.2%。</p>
<p>调整后的营业收入增长 2%，达到 4.67 亿欧元，调整后的营业利润率从去年的 9.4% 提高至 10.1%。</p>
<p>集团收入从去年的 48.8 亿欧元下降 6%，降至 46.1 亿欧元。按固定汇率计算，收入增长 3%，而按有机基础计算，增长 4%，所有运营部门均实现增长。</p>
<p>展望 2026 财年，Fresenius Medical Care 预计调整后的营业收入将保持在一个稳定水平，预计与去年相比的增长率在正负中间个位数百分比之间。</p>
<p>预计收入增长与去年相比仍将基本持平。2026 年的预期增长率为固定汇率。</p>
<p>在 2025 财年，调整后的营业收入为 22.12 亿欧元，收入为 196.28 亿欧元。</p>
<p>该公司补充说，预计在 2026 年将节省 2.5 亿欧元，并产生 3.5 亿欧元的一次性费用。FME25+ 节省预计到 2027 年底将总计达到 12 亿欧元。</p>
<p>在德国 XETRA 市场，股票交易价格为 37.24 欧元，下跌 4.2%。</p>
<p>在纽约证券交易所的盘前交易中，股票交易价格为 21.68 美元，下跌 4.3%。</p>
<p>有关更多收益新闻、收益日历和股票收益，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

<p>Fresenius Medical Care AG 报告第一季度净收入下降 22%，导致其股价下跌 4%。净收入降至 1.18 亿欧元，基本每股收益降至 0.43 欧元。集团收入下降 6%，至 46.1 亿欧元，尽管调整后的营业收入增长了 2%。该公司维持其 2026 财年的展望，预计调整后的营业收入将保持稳定，收入增长持平。其股票在德国交易价格为 37.24 欧元，在纽约证券交易所为 21.68 美元，均下跌约 4%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Shares of Fresenius Medical Care AG (FMS,FME.DE) were losing around 4 percent in German trading as well as in pre-market activity on the NYSE, after the company reported lower profit and revenues in its first quarter. Further, the German provider of products and services for patients with renal diseases maintained fiscal 2026 outlook.</p>
<div class="lb-trans"><p>Fresenius Medical Care AG（FMS,FME.DE）的股票在德国交易中下跌约 4%，在纽约证券交易所的盘前交易中也出现类似情况，此前该公司报告第一季度利润和收入下降。此外，这家德国肾病患者产品和服务的供应商维持了 2026 财年的展望。</p>
</div><p>In the first quarter, net income attributable to shareholders decreased 22 percent to 118 million euros from last year's 151 million euros in the prior year. Basic earnings per share fell 17 percent to 0.43 euro from 0.52 euro a year ago.</p>
<div class="lb-trans"><p>在第一季度，归属于股东的净收入从去年的 1.51 亿欧元下降 22%，降至 1.18 亿欧元。基本每股收益从去年的 0.52 欧元下降 17%，降至 0.43 欧元。</p>
</div><p>Adjusted net income was 251 million euros or 0.91 euro per share, compared to 246 million euros or 0.84 euro per share a year earlier.</p>
<div class="lb-trans"><p>调整后的净收入为 2.51 亿欧元，或每股 0.91 欧元，而去年同期为 2.46 亿欧元，或每股 0.84 欧元。</p>
</div><p>In the first quarter, Group operating income decreased 14 percent from last year to 286 million euros, resulting in a margin of 6.2 percent, down from 6.8 percent last year.</p>
<div class="lb-trans"><p>在第一季度，集团营业收入从去年下降 14%，降至 2.86 亿欧元，利润率从去年的 6.8% 降至 6.2%。</p>
</div><p>Adjusted operating income increased 2 percent to 467 million euros, and adjusted operating margin improved to 10.1 percent from 9.4 percent last year.</p>
<div class="lb-trans"><p>调整后的营业收入增长 2%，达到 4.67 亿欧元，调整后的营业利润率从去年的 9.4% 提高至 10.1%。</p>
</div><p>Group revenue decreased 6 percent to 4.61 billion euros from 4.88 billion euros a year ago. Revenues increased 3 percent at constant currency, while the growth was 4 percent on an organic basis with growth in all operating segments.</p>
<div class="lb-trans"><p>集团收入从去年的 48.8 亿欧元下降 6%，降至 46.1 亿欧元。按固定汇率计算，收入增长 3%，而按有机基础计算，增长 4%，所有运营部门均实现增长。</p>
</div><p>Looking ahead for fiscal 2026, Fresenius Medical Care expects adjusted operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year.</p>
<div class="lb-trans"><p>展望 2026 财年，Fresenius Medical Care 预计调整后的营业收入将保持在一个稳定水平，预计与去年相比的增长率在正负中间个位数百分比之间。</p>
</div><p>Revenue growth is still projected to be broadly flat compared to prior year. The expected growth rates for 2026 are at constant currency.</p>
<div class="lb-trans"><p>预计收入增长与去年相比仍将基本持平。2026 年的预期增长率为固定汇率。</p>
</div><p>In fiscal 2025, adjusted operating income was 2.212 billion euros and revenue was 19.628 billion euros.</p>
<div class="lb-trans"><p>在 2025 财年，调整后的营业收入为 22.12 亿欧元，收入为 196.28 亿欧元。</p>
</div><p>The firm added that it expects 250 million euros savings and 350 million euros related one-time costs in 2026. FME25+ savings are expected to total 1.2 billion euros by the end of 2027.</p>
<div class="lb-trans"><p>该公司补充说，预计在 2026 年将节省 2.5 亿欧元，并产生 3.5 亿欧元的一次性费用。FME25+ 节省预计到 2027 年底将总计达到 12 亿欧元。</p>
</div><p>On the XETRA in Germany, the shares were trading at 37.24 euros, down 4.2 percent.</p>
<div class="lb-trans"><p>在德国 XETRA 市场，股票交易价格为 37.24 欧元，下跌 4.2%。</p>
</div><p>In pre-market activity on the NYSE, the shares were trading at $21.68, down 4.3 percent.</p>
<div class="lb-trans"><p>在纽约证券交易所的盘前交易中，股票交易价格为 21.68 美元，下跌 4.3%。</p>
</div><p>For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.</p>
<div class="lb-trans"><p>有关更多收益新闻、收益日历和股票收益，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

费森尤斯医疗护理第一季度业绩下滑，但仍维持 2026 财年展望；股价下跌